LLY logo

Lilly (Eli)

LLY · What the business does, what can go wrong, and how options sellers approach it

What it does

Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures and sells prescription medicines. Its work centers on cardiometabolic health (diabetes and obesity), cancer, immunology and neuroscience.

Well-known products include Mounjaro and Zepbound (tirzepatide), Trulicity, Jardiance, Humalog and Humulin for cardiometabolic conditions, Verzenio for cancer, and Taltz and Olumiant for immune-related conditions.

How it makes money

Lilly sells branded drugs, mostly through wholesalers, pharmacies and healthcare systems, and is paid by insurers, government programs and patients. Revenue depends on prescription volume and the net price after rebates and discounts.

Patents give a drug a period of exclusivity. After they expire, generic or biosimilar competitors can take much of the sales, so the company must keep bringing new drugs to market.

Why investors own it

  • Exposure to large, long-lasting medical needs, including diabetes, obesity and cancer.
  • A research pipeline that could replace older products as their patents expire.
  • Manufacturing scale, which matters for drugs in high demand.
  • A dividend, though it is not guaranteed and can change.

What can go wrong

  • Clinical trial failures or regulatory setbacks.
  • Patent expirations and new competition, including from other makers of obesity and diabetes drugs.
  • Pricing pressure from governments, insurers and pharmacy benefit managers.
  • Supply constraints or safety issues affecting a key product.
  • Concentration risk: if a few drugs drive most growth, problems with one can move the whole stock.

What to watch

  • Prescription trends for the main cardiometabolic drugs
  • Clinical trial readouts and regulatory decisions
  • Manufacturing capacity expansion
  • Insurance coverage and drug pricing policy
  • Patent expiration dates and competitor launches
  • Gross margin and research spending

Options income angle

Options on LLY are generally liquid, with many strikes and expirations and tight bid-ask spreads on near-the-money contracts. Implied volatility tends to rise around earnings, major trial results, regulatory decisions and shifts in drug pricing policy.

One caution: a stock like this can gap sharply on a single trial result or policy headline. A covered call can cap gains in a sudden rally, and a cash-secured put can leave you owning shares after a steep drop.

This is general education, not advice.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 12, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Eli Lilly's 2025 revenue and profit grew sharply, and almost all of the growth came from two drugs, Mounjaro and Zepbound. The filing ties the company's near-term prospects to those drugs: U.S. pricing deals, Medicare access and the review of a new obesity pill, orforglipron. It also says the company is spending heavily to build manufacturing capacity.

How the business did

  • Revenue was $65,179 million versus $45,043 million in 2024, up 45 percent. Net income was $20,640 million versus $10,590 million, and diluted earnings per share were $22.95 versus $11.71.
  • Higher volume added 50 percent to revenue, while lower realized prices (what the company actually collects after discounts and rebates) subtracted (6) percent. Mounjaro and Zepbound drove both effects.
  • Mounjaro revenue was $22,965 million versus $11,540 million. Zepbound was $13,542 million versus $4,926 million. Verzenio rose to $5,723 million from $5,307 million.
  • Gross margin was 83.0 percent of revenue versus 81.3 percent. Research and development spending rose 21 percent and marketing, selling and administrative spending rose 29 percent, mainly for launches.
  • Operating cash flow was $16.8 billion versus $8.8 billion. Capital expenditures were $7.8 billion. The company repurchased $4.1 billion of shares and paid dividends of $6.00 per share. Total debt rose to $42.5 billion from $33.6 billion.

Risks specific to this company

  • Product concentration: Mounjaro and Zepbound were 56 percent of total revenues in 2025. Six products with more than $3 billion of revenue each made up 82 percent.
  • Government price-setting: Under a U.S. law known as the IRA, Medicare prices are set by the government. Jardiance is covered in 2026, and Trulicity and Verzenio were selected in January 2026 for 2028. The filing expects more products to be selected.
  • U.S. pricing agreements: In November 2025 the company announced preliminary voluntary agreements with the U.S. government to lower Medicaid and certain other prices. The definitive terms are not final, and the added obesity-drug access may not bring in enough revenue to offset the price concessions.
  • Insurer coverage: In July 2025, CVS Caremark stopped covering Zepbound as a preferred obesity medicine on some plans, which hurt access for patients on those plans.
  • Counterfeit and compounded copies: The filing reports continued sales of counterfeit and mass-compounded versions of incretin drugs, the class that includes Mounjaro and Zepbound. Stopping them is costly and may not work.
  • China and tariffs: The company relies on China-based suppliers for parts of its supply chain, and replacing them could take significant time and expense. It also says it may not be able to share tariff costs to any meaningful degree. Separately, it is mostly self-insured against litigation losses for its marketed products.

What management is watching

  • Near-term results depend on the timing of approvals for orforglipron and on Medicare access for Zepbound. Medicare beneficiaries are to have access to discounted obesity medicines by July 1, 2026. Management also cites uptake in new incretin channels and markets.
  • Orforglipron for obesity was submitted in the U.S., the EU and Japan, and it received an FDA priority voucher that speeds review. A retatrutide Phase 3 trial met all primary and key secondary endpoints.
  • Capital spending is expected to be meaningfully higher in the near term as manufacturing capacity expands. Supply agreements could require payments of up to approximately $10 billion if specified purchase amounts are not met.
  • Management has signed acquisition agreements in 2026, with potential closing payments below $3 billion. It also flags that swings in incretin volume from channel dynamics or demand can have an outsized effect in any one period.
  • The quarterly dividend was raised to $1.73 per share, an indicated annual rate of $6.92 per share for 2026. The company had $10.9 billion remaining on its share repurchase program.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Lilly reported revenue of $24,397 million for the third quarter, up 39 percent from $17,601 million a year earlier. Net income rose 16 percent to $6,451 million. Higher sales volume of Mounjaro and Zepbound drove the growth, partly offset by lower realized prices. Profit grew more slowly than revenue because of a large charge for acquired in-process research and development (drug candidates bought while still in testing, expensed immediately).

How the business did

  • Revenue: Nine-month revenue was $67,170 million, up 46 percent from $45,887 million. For the quarter, volume added 53 percent to revenue while lower prices took away 15 percent. Outside the U.S., lower prices were mainly tied to Mounjaro's inclusion on China's National Reimbursement Drug List.
  • Products: Mounjaro brought in $10,723 million and Zepbound $5,352 million for the quarter. Trulicity fell 14 percent to $904 million and Taltz fell 5 percent to $856 million. Mounjaro, Zepbound and Foundayo made up 66 percent of nine-month revenue.
  • Profit: Diluted earnings per share were $7.22, versus $6.21 a year earlier, and $23.42 for nine months. Gross margin was 83.9 percent of revenue, compared with 82.9 percent. Acquired IPR&D charges were $4,181 million, compared with $656 million, mostly from the AtaiBeckley and Curevo deals. Research and development spending rose 23 percent to $4,247 million.
  • Cash and capital return: The company paid $18.2 billion for business development in nine months. Total debt reached $49.5 billion, up $7.0 billion from year-end, and cash fell to $4.9 billion from $7.3 billion. The company repurchased $4.3 billion of shares and paid dividends of $4.6 billion. It declared a fourth-quarter dividend of $1.73 per share.

What management is watching

  • Near-term results depend on the timing of further orforglipron (Foundayo) approvals and on uptake in new channels, including U.S. Medicare for Zepbound and Foundayo. Under the Medicare GLP-1 Bridge program, Medicare beneficiaries have discounted access from July 1, 2026 through December 31, 2027. Management says continued uptake is unknown.
  • Management expects higher capital spending in the near term for manufacturing expansion. Additional capacity is expected to come online over the next several years. It also points to promotional spending for launches and ongoing deal-making, including the October 2026 Merida acquisition for up to $2.9 billion.
  • Management says incretin volume swings from channel dynamics or demand can have a disproportionate effect on results in any one period. Incretins are the obesity and diabetes drugs behind Mounjaro and Zepbound.
  • Pricing pressure continues. Under the Inflation Reduction Act, Medicare prices for Trulicity and Verzenio will be government-set starting in 2028. Management expects other significant products to be selected in future years.

Follow LLY in Kortex

The Kortex app shows LLY's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.